About BIMINI Biotech

BIMINI Biotech develops first-in-class therapeutics targeting the Wiskott-Aldrich-Syndrome protein (WASp) to treat hematological cancers. Their proprietary small molecule WASP modulators demonstrate potent anti-cancer effects, addressing the need for effective treatments in this challenging area of oncology.

```xml <problem> Many hematological cancers, such as lymphoma and leukemia, have high relapse rates and limited treatment options, especially for elderly patients with comorbidities. Current therapies often fail, and newer targeted agents with novel mechanisms of action are needed to improve treatment outcomes. </problem> <solution> BIMINI Biotech is developing first-in-class small molecule therapeutics that target the Wiskott-Aldrich Syndrome protein (WASp), an actin nucleation-related protein expressed exclusively in hematopoietic cells. Their proprietary WASp modulators, including agonists and antagonists, have demonstrated potent anti-cancer effects by inducing genomic instability in lymphoma cells, leading to cancer cell death. BIMINI's lead candidate, BM-011, a WASp activator, has shown promising in vitro and in vivo anti-cancer effects across various lymphoma models, including those resistant to existing treatments. By modulating WASp, BIMINI aims to provide a novel therapeutic approach for hematological malignancies and autoimmune disorders. </solution> <features> - Proprietary portfolio of small molecule WASp modulators (agonists and antagonists) - BM-011: A WASp agonist demonstrating potent activity in various lymphoma models - Unique mechanism of action inducing genomic instability in lymphoma cells - Potential application in autoimmune disorders through WASp modulation - In vitro and in vivo validation of anti-cancer effects for different lymphoma models </features> <target_audience> The primary target audience includes patients with relapsed or refractory lymphomas and leukemias, as well as researchers and clinicians seeking novel therapeutic approaches for hematological malignancies and autoimmune disorders. </target_audience> ```

What does BIMINI Biotech do?

Where is BIMINI Biotech located?

BIMINI Biotech is based in Leiden, The Netherlands.

When was BIMINI Biotech founded?

BIMINI Biotech was founded in 2019.

How much funding has BIMINI Biotech raised?

BIMINI Biotech has raised 5290000.

Location

Leiden, The Netherlands

Founded

2019

Funding

5290000

Employees

4 employees

Major Investors

Torrey Pines Investment

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

BIMINI Biotech

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

biminibiotech.nl 500+

Crunchbase

Founded 2019 – Leiden, The Netherlands

Funding

Estimated Funding

$5M+

Major Investors

Torrey Pines Investment

Team (<5)

No team information available.

Company Description

Problem

Many hematological cancers, such as lymphoma and leukemia, have high relapse rates and limited treatment options, especially for elderly patients with comorbidities. Current therapies often fail, and newer targeted agents with novel mechanisms of action are needed to improve treatment outcomes.

Solution

BIMINI Biotech is developing first-in-class small molecule therapeutics that target the Wiskott-Aldrich Syndrome protein (WASp), an actin nucleation-related protein expressed exclusively in hematopoietic cells. Their proprietary WASp modulators, including agonists and antagonists, have demonstrated potent anti-cancer effects by inducing genomic instability in lymphoma cells, leading to cancer cell death. BIMINI's lead candidate, BM-011, a WASp activator, has shown promising in vitro and in vivo anti-cancer effects across various lymphoma models, including those resistant to existing treatments. By modulating WASp, BIMINI aims to provide a novel therapeutic approach for hematological malignancies and autoimmune disorders.

Features

Proprietary portfolio of small molecule WASp modulators (agonists and antagonists)

BM-011: A WASp agonist demonstrating potent activity in various lymphoma models

Unique mechanism of action inducing genomic instability in lymphoma cells

Potential application in autoimmune disorders through WASp modulation

In vitro and in vivo validation of anti-cancer effects for different lymphoma models

Target Audience

The primary target audience includes patients with relapsed or refractory lymphomas and leukemias, as well as researchers and clinicians seeking novel therapeutic approaches for hematological malignancies and autoimmune disorders.